Results 171 to 180 of about 105,598 (267)

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, Volume 183, Issue 8, Page 1640-1652, April 2026.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. [PDF]

PeerJ
Fan J, Song Y.
europepmc   +1 more source

Novel Silver(I) and Gold(I) N‐Heterocyclic Carbene Complexes Induce ROS‐Dependent Autophagic Cell Death in Human Hepatoma Cell Line HepG2

Chemical Biology &Drug Design, Volume 107, Issue 4, April 2026.
In this research work, the cytotoxicity of eight sulfonated silver(I) and gold(I) N‐heterocyclic carbene (NHC) complexes—four newly synthesized—was evaluated against human liver cancer cells. Two compounds showed selectivity for cancer cells, inducing ROS‐dependent autophagic cell death via AKT/mTOR pathway inhibition without triggering apoptosis ...
Rocchina Miglionico, Francesco Viceconte, Maria Francesca Armentano, Annaluisa Mariconda, Ilaria Nigro, Pasquale Longo, Faustino Bisaccia   +6 more
wiley   +1 more source

Poly-ADP-ribosylation modulated by poly(ADP-ribose) polymerase 1 is associated with glucose metabolism in colorectal cancer cells. [PDF]

Transl Oncol
Zhang C, Wang P, Yu J, Yuan J, Zhang L, Li M.   +5 more
europepmc   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer. [PDF]

Front Oncol
Uekusa R, Yokoi A, Watanabe E, Inoue M, Mizuno K, Yoshida K, Yoshikawa N, Niimi K, Suzuki S, Kajiyama H.   +9 more
europepmc   +1 more source

Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma. [PDF]

BMC Cancer
Toyohara Y, Sone K, Kumegawa K, Yamamoto Y, Hachijo R, Kukita A, Taguchi A, Ikemura M, Miyamoto Y, Tanikawa M, Iriyama T, Mori M, Hamamoto R, Ushiku T, Oda K, Hirota Y, Maruyama R, Osuga Y.   +17 more
europepmc   +1 more source

Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]

J Ovarian Res
Zhang B, Lv W, Fu Z, Zhou Y, Du J, Yao Q, Qian Q, Bu H.   +7 more
europepmc   +1 more source

Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1. [PDF]

Molecules
Morgan I, Rennert R, Berger R, Hassanin A, Davari MD, Eisenschmidt-Bönn D, Wessjohann LA.   +6 more
europepmc   +1 more source

Poly (ADP-Ribose) Polymerase 1 and 2 in B-Cell Lymphoma: Pathogenic Roles and Therapeutic Implications. [PDF]

Am J Pathol
Molina-Alvarez A, Sanchez-Gonzalez B, Colomo L, Yélamos J.   +3 more
europepmc   +1 more source